2,4-dinitrophenyl vinyl ether | 7287-46-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dinitrophenyl vinyl ether
• 英文别名: Vinyl-(2,4-dinitro-phenyl)-ether；2,4-Dinitrophenyl vinyl ether；1-ethenoxy-2,4-dinitrobenzene
• CAS: 7287-46-9
• 化学式: C₈H₆N₂O₅
• 分子量: 210.146
• InChiKey: SRFOJWNBDIERJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,4-二硝基酚 、 四乙烯基锡 在 氧气 、 copper diacetate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以4%的产率得到2,4-dinitrophenyl vinyl ether
  参考文献：
  名称：

  [EN] THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAME
  [FR] DÉRIVÉS DE DNP THÉRAPEUTIQUES ET PROCÉDÉS LES UTILISANT

  摘要：

  公开号：

  WO2015031598A3

文献信息

• THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAME
  申请人：YALE UNIVERSITY

  公开号：US20160207873A1

  公开（公告）日：2016-07-21

  The present invention includes DNP derivatives of formula (I) that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

  本发明涉及式(I)的DNP衍生物，适用于预防或治疗需要该治疗的受试者的代谢性疾病或紊乱。在某些实施例中，该受试者进一步接受至少一种额外的治疗药物。
• Therapeutic DNP derivatives and methods using same
  申请人：Yale University

  公开号：US10457629B2

  公开（公告）日：2019-10-29

  The present invention includes DNP derivatives of formula (I) that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

  本发明包括式（I）的 DNP 衍生物，可用于预防或治疗有需要的受试者的代谢疾病或紊乱。在某些实施方案中，受试者进一步施用至少一种额外的治疗剂。
• Organomercury Chemistry. A Novel Synthesis of Vinyl Esters, Vinyl Ethers and Vinyl Thioethers¹
  作者：Donald J. Foster、Erich Tobler

  DOI：10.1021/ja01465a028

  日期：1961.2
• RETT SYNDROME AND TREATMENTS THEREFORE
  申请人：Rett Syndrome Research Trust

  公开号：EP3013371A1

  公开（公告）日：2016-05-04
• [EN] RETT SYNDROME AND TREATMENTS THEREFORE<br/>[FR] SYNDROME DE RETT ET SES TRAITEMENTS
  申请人：RETT SYNDROME RES TRUST

  公开号：WO2014210389A1

  公开（公告）日：2014-12-31

  The present invention provides new strategies for the treatment of Rett Syndrome and other MECP2-associated disorders, including for the identification and/or characterization of useful therapeutic modalities and/or for the stratification of Rett Syndrome patients to identify those more or less likely to respond to a particular therapy. In some embodiments, the present invention defines certain components of metabolic pathways, and particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways, most particularly of lipid and/or cholesterol metabolism (e.g., biosynthesis) pathways in the brain, as targets useful in the identification and/or characterization of potential Rett Syndrome treatment agents. Among other things, the present invention provides systems for identifying and/or characterizing such agents by contacting them with a system that comprises one or more such metabolic pathway components, and assessing their impact on presence, level, activity, and/or form of one or more indicators (e.g., components, products, and/or markers of the relevant pathway(s)).